Article
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.
Oncotarget - 15 Apr 2014
Jardim Denis L Fontes, de Melo Gagliato Debora, Falchook Gerald S, Janku Filip, Zinner Ralph, Wheler Jennifer J, Subbiah Vivek, Piha-Paul Sarina A, Fu Siqing, Murphy Mariela Blum, Ajani Jaffer, Tang Chad, Hess Kenneth, Hamilton Stanley R, Roy-Chowdhuri Sinchita, Kurzrock Razelle, Meric-Bernstam Funda, Hong David S
Abstract excerpt
We sought to investigate the demographics and tumor-associated features in patients with gastroesophageal (GE) malignancies referred to our Phase I Program who had formalin-fixed, paraffin-embedded tissue from archival or new biopsies tested for MET mutation and/or amplification. MET amplification was found in 5 of 76 (6.6%) patients (3/34 [8.8%] esophageal, 2/26 [7.7%] gastric and none in 22 gastroesophageal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.